Stop outsourcing, start partnering: Redefining value in global clinical trial execution
As biopharma pipelines expand and development timelines compress, the traditional outsourcing model is reaching its limits. While outsourcing may add capacity, it rarely delivers the agility, integration or foresight needed to manage today’s global trial complexity.
What’s needed now is a fundamental shift: from transactional service provision to true strategic partnership.
In this webinar, Sheng Cui, Chief Manufacturing Officer at NewAmsterdam Pharma, and Luke Wilson, Sr. Director of Biotech Commercial Operations at Thermo Fisher Scientific, explore how rethinking the CDMO relationship enabled NewAmsterdam Pharma to manage 11 global studies across 51 countries—while operating with a lean internal team.
You’ll gain insight into how they:
- Reframed the CDMO as a value-driving partner, not just a supplier
- Used real-time forecasting and simulation tools to align supply with actual patient enrollment
- Avoided delays, reduced waste, and maintained 100% on-time delivery
- Balanced cost, risk, and quality—without compromising patient access
Join us to explore what redefining value really looks like in practice, and why the future of clinical execution depends on stronger, more strategic partnerships.
Complete the form to watch on-demand
Watch on-demand now →Meet the Speakers
Sheng Cui
Chief Manufacturing Officer at NewAmsterdam Pharma
Luke Wilson
Senior Director of Biotech Commercial Operations at Thermo Fisher Scientific
Inspire. Connect. Innovate.
